ERBB2 and breast carcinoma: All patients with HER2-positive breast cancer had previously received anti-HER2 therapy, among which the most common treatments were trastuzumab (n = 107, 95.5%), pyrotinib (n = 75, 67.0%) and pertuzumab (n = 38, 33.9%).